Histogen: Clinical Trials

6 trials sponsored by Histogen, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 terminated, 2 unknown. 5 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Terminated 2, Unknown 2, Completed 1
Phase 22Completed 1, Unknown 1

Follow Histogen: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Human ECM Implanted Within Microfracture Interstices & the Cartilage Defect in the Knee to Regenerate Hyaline Cartilage
microfracture surgery + HST003 - Articular Cartilage Disorder of Knee, Cartilage Damage
Phase 1TerminatedHistogen12021-11-152023-01-19
Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19
Emricasan, Placebo - Covid19
Phase 1TerminatedHistogen132021-03-112022-01-04
Safety and Efficacy of HST 001 in Male Pattern Hair Loss
HST 001, Phosphate Buffered Saline - Male Pattern Hair Loss
Phase 1CompletedHistogen362020-05-262021-03-19
Safety and Tolerability of Hair Stimulating Complex (HSC) in Female Pattern Hair Loss
Hair Stimulating Complex (HSC), Phosphate Buffered Saline - Alopecia
Phase 1UnknownHistogen272018-07-022019-02-21
Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
Emricasan, Placebo - Cirrhosis, Portal Hypertension
Phase 2CompletedHistogen2632016-10-172022-02-11
Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia
Hair Stimulating Complex (HSC), Dulbecco's Modified Eagle Medium, DMEM - Androgenetic Alopecia
Phase 1 / Phase 2UnknownHistogen562011-12-012012-01-18

Conditions studied

Alopecia (2)  ·  COVID-19 (1)  ·  Fibrosis (1)  ·  Fractures, Stress (1)  ·  Hypertension, Portal (1)  ·  Liver Cirrhosis (1)  ·  Lymphoma, Follicular (1)  ·  Non-alcoholic Fatty Liver Disease (1)

Interventions

3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (2)

Countries

United States (5)  ·  Germany (1)  ·  Philippines (1)  ·  Spain (1)

Top investigators

Jeanette M Wetzel (1)  ·  Julieta P. Arambulo, MD (1)  ·  Mark A Hubka (1)  ·  Raavi Gupta, MD (1)  ·  Ruqayyah Abdulrahoof (1)  ·  Samuel Mboggo (1)  ·  Theresa Marie Reyes-Cacas, MD (1)

Results publications

PMID 31870950